Recombinant von Willebrand factor (rVWF), marketed as Vonvendi, is a non-plasma-derived treatment used for patients with von Willebrand disease (VWD) who do not respond to desmopressin. It contains only VWF, allowing for precise control of factor VIII levels, which is especially helpful for patients at risk of FVIII accumulation or thrombosis. 

Vonvendi is given by intravenous infusion and is effective in managing surgery, acute bleeding, and severe VWD (types 2 and 3). Unlike plasma-derived products, it eliminates the risk of blood-borne infections. Patients or providers may choose it over other treatments when avoiding plasma products is preferred or when more flexible, targeted replacement of VWF and FVIII is needed.